Connect with us

News

Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

gbafNews28

– In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 –

– Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 –

WALTHAM, Mass., Jan. 10, 2021 — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data from its myotonic dystrophy type 1 (DM1) program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease.

Dyne’s FORCE™ platform leverages the importance of transferrin 1 receptor, TfR1, in muscle biology as the foundation for its novel approach. TfR1, which is highly expressed on the surface of muscle cells, is required for iron transport into muscle cells. Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. Dyne’s DM1 lead candidate consists of a Fab conjugated to an antisense oligonucleotide (ASO) to enable targeted delivery to muscle tissue to reduce accumulation of toxic DMPK RNA in the nucleus, release splicing proteins, allow normal mRNA processing and translation of normal proteins, and potentially stop or reverse the disease.   

These new preclinical data build on previous results showing significant reduction in cytoplasmic wild type DMPK RNA in a mouse model that expresses human TfR1(hTfR1). To assess the ability of its lead DM1 candidate to reduce toxic human nuclear DMPK RNA, Dyne developed an innovative hTfR1/DMSXL mouse model that expresses the human TfR1 and carries a human DMPK gene that represents a severe DM1 phenotype with more than 1,000 CTG repeats. In this model, two doses (2 x 10 mg/kg) of Dyne’s candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days: 60 percent in the heart; 56 percent in the diaphragm; 54 percent in the tibialis anterior and 39 percent in the gastrocnemius. In the study, Dyne’s candidate was well tolerated. Dyne expects to share data from the hTfR1/DMSXL model at a scientific meeting during 2021.

“At Dyne we are focused on developing therapies designed to target the genetic basis of the disease with the goal of delivering disease modification for patients,” said Romesh Subramanian, Ph.D., chief scientific officer of Dyne. “Multiple genetic studies in DM1 have suggested that a 30 to 50 percent knockdown of toxic human DMPK has the potential to be disease modifying. We are very pleased with the robust toxic human DMPK reduction observed in the hTfR1/DMSXL model, which, along with our previous preclinical data showing correction of splicing and reversal of myotonia, indicates the potential to have an impact for patients living with a disease with no approved therapies. We intend to utilize this novel model to conduct IND-enabling work as we progress toward the clinic.”

“In DM1, it is critical to target the nucleus where the disease-causing toxic DMPK resides and forms foci,” said Valeria Sansone, M.D., Ph.D., Clinical and Scientific Director, Clinical Center NeMO, Milan; Associate Professor of Neurology, University of Milan. “The innovative preclinical model used in this study has the potential for translation into human disease. The data demonstrate compelling reduction in levels of DMPK RNA and suggest this approach may be effective in targeting nuclear DMPK and delivering a therapeutic to muscle for diseases such as DM1.”

The new preclinical data from the hTfR1/DMSXL model are included in an updated corporate presentation available in the Investors & Media section of the Company’s website and add to the robust in vitro and in vivo findings generated previously in Dyne’s DM1 program:

  • Reduction in nuclear foci and correction of splicing in DM1 patient cells
  • Correction of splicing and reversal of myotonia in well-validated HSALR model
  • Enhanced muscle distribution as evidenced by reduced levels of cytoplasmic wild type DMPK RNA in non-human primates (NHPs)
  • Durability of response of up to 12 weeks after a single dose in a wild type mouse model
  • Favorable tolerability observed in multiple NHP studies

“Today’s exciting data further validate our FORCE platform which drives our efforts to deliver targeted, modern oligonucleotide therapies with the potential to be life-transforming for patients with serious muscle diseases,” said Joshua Brumm, president and chief executive officer of Dyne. “We remain on track to submit INDs for our three programs between the fourth quarter of 2021 and the fourth quarter of 2022, with DM1 and DMD submissions anticipated in the earlier part of that window, followed later by FSHD.”

About Myotonic Dystrophy Type 1 (DM1)

DM1 is a rare, progressive, genetic disease that affects skeletal, cardiac and smooth muscles. It is a monogenic, autosomal dominant disease caused by an abnormal expansion in a region of the DMPK gene. The expansion in the number of CTG triplet repeats causes toxic RNA to cluster in the nucleus, forming nuclear foci and altering the splicing of multiple proteins essential for normal cellular function. This altered splicing results in a wide range of symptoms. People living with DM1 typically experience progressive weakness of major muscle groups, which can affect mobility, breathing, heart function, speech, digestion and vision as well as cognition. DM1 is estimated to affect more than 40,000 people in the United States and over 74,000 people in Europe, but there are currently no approved disease-modifying therapies.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company is utilizing its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit www.dyne-tx.com, and follow us on TwitterLinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects, plans, objectives of management, the expected timeline for submitting investigational new drug applications, the potential advantages of Dyne’s FORCE platform and programs, expectations regarding the translation of preclinical findings to human disease and plans to conduct additional preclinical studies, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and Dyne’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; Dyne’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on Dyne’s business and operations; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contact:

Dyne Therapeutics Amy Reilly [email protected] 857-341-1203

 

Primary Logo

News

Kerry Logistics Network Extends Winning Streak at the Quamnet Outstanding Enterprise Awards for Sixth Year Running

gbafNews28

HONG KONG SAR – Media OutReach – 22 February 2021 – Kerry Logistics Network Limited (‘Kerry Logistics Network’; Stock Code 0636.HK) is honoured to be named the Outstanding Global 3PL for the fourth time running at the Quamnet Outstanding Enterprise Awards (‘QOEA’) 2020. This was the sixth consecutive year that Kerry Logistics Network has been a winner of QOEA, which were announced in Hong Kong today.

Organised annually by leading Hong Kong financial news platform Quamnet, the QOEA aim to appraise and recognise the distinguished enterprises in Hong Kong and its spirit. Themed “Sagacity Built to Business Perfection” this year, the QOEA 2020 commended enterprises’ outstanding sagacity in times of challenge and change. Winning companies were nominated and selected by the judging committee made up of the Quamnet editorial team, the Quam Research team and independent financial analysts.

William Ma, Group Managing Director of Kerry Logistics Network, said, “2020 was a trying year filled with unprecedented challenges, which we strived to navigate and adapted to with ingenuity and flexibility. Therefore, we are particularly delighted to be awarded the Outstanding Global 3PL title again for the recognition of our efforts during the year. Logistics will continue to serve a crucial function globally in the times ahead. We will remain dedicated to excellence and innovation as we work hard to ensure smoothly-run supply chains.”

Kerry Logistics Network has been offering innovative solutions and expanding its geographic coverage to strengthen its service capability and diversify its business portfolio. It has launched new multimodal transport products to Mongolia, through its member Globalink Logistics, to provide alternative solutions to customers, as well as announced recently its development of a bonded logistics centre in the Hainan Free Trade Port in China to tap into the growing duty-free and inbound e-commerce market.

About Kerry Logistics Network Limited (Stock Code 0636.HK)

Kerry Logistics Network is an Asia-based, global 3PL with a highly diversified business portfolio and the strongest coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal), industrial project logistics, to cross-border e-commerce, last-mile fulfilment and infrastructure investment.

With a global presence across 59 countries and territories, Kerry Logistics Network has established a solid foothold in half of the world’s emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.

Kerry Logistics Network generated a revenue of over HK$40 billion in 2019 and is the largest international logistics company listed on the Hong Kong Stock Exchange.

About Quamnet Outstanding Enterprise Awards

Instituted in 2009, QOEA is organised by Quamnet, a leading financial website in Hong Kong, to identify and praise the excellent performance of Hong Kong enterprises. It has developed into an annual event with wide recognition and support from independent investors, media and industries.

Continue Reading

News

Citibank Officially Launches Citi Plus®

gbafNews28

Co-creating With Target Clients to Suit Their Banking and Investment Needs

Fostering Financial Education to Level-Up Digital Natives Through Mobile Banking

HONG KONG SAR – Media OutReach – 22 February 2021 – Citigroup Inc. (NYSE symbol: C) – Citibank announced today the official launch of Citi Plus®, a digital value proposition offering financial education and a novel banking experience to level-up digital natives through mobile banking. Citi Plus® clients can obtain personalized wealth management information and knowledge kits to accumulate their wealth and earn more through accomplishing fun tasks.

Having its pilot launch in early December 2020, Citi Plus® accumulated nearly 5,000 registrants, who are interested in the new service, in the first three weeks. “Citibank Hong Kong has shown strong determination in the development of digital banking in recent years. Citi Plus® is our latest initiative to bring digital natives a banking experience they admire,” said Mr Lawrence Lam, Consumer Business Manager of Citibank Hong Kong. “Millennials were invited to participate in research and the co-creation process, through which we could better address target clients’ pain points, and help them grow their wealth via the new service.”

Citi Plus® offers a range of investment products to clients including stocks, money market funds as well as an array of mutual funds primarily from Aberdeen Standard Investments, Allianz Global Investors and Franklin Templeton.

One of the key features of Citi Plus® is a series of financial wellness modules specially designed to educate clients and guide their thinking when it comes to making decisions about managing money, building wealth and achieving financial goals. These engaging modules enhance wealth inclusion, allow clients to build healthy financial habits and achieve targets responsibly.

  • Wealth Smart: A financial literacy guide covering a series of easy-to-follow courses and quizzes, with bite-sized content that helps clients level-up and approach investments with greater confidence. Clients can learn at their own pace, whilst keeping themselves abreast of the times and acquiring financial knowledge.
  • Wealth Digest[1]: A personalized series of news, articles and insights on wealth which are updated continually to help clients make informed investment decisions.
  • Money Goal[2]: A personal goal tracking tool that helps clients define financial objectives and track their progress towards these targets.

Alongside this step-by-step guidance providing clients with financial knowledge and resources, Citi Plus® also offers innovative features that engage clients and help them level-up along their financial journey.

  • Deposit: “Citi Interest Booster” enables clients to earn additional bonus interest (up to 1.8% p.a.[3]) on savings by completing simple missions. Beginning with a base interest rate of 0.3% p.a., clients can complete “missions” ­– such as maintaining balance, funding-in, spending with Citi Plus® cards, investment and currency exchange — to boost interest rates up to 1.8% p.a. [3]
  • Investment[4]: Citi Plus® offers a reliable investment platform that allows clients not only to trade stocks, but also to invest in mutual funds. With progressive self-learning resources and low investment thresholds, clients have the flexibility to choose their investment options.

o “Flexi Wealth” allows clients to start investing in money market funds with as little as HK$1, and to conduct transactions at their convenience, without any transaction charges or monthly service fees.

o Our suggested mutual fund portfolios based on clients’ financial goals and risk profiles will also be offered, featuring mutual funds primarily from Aberdeen Standard Investments, Allianz Global Investors and Franklin Templeton at a minimum of HK$100, thus giving clients a hassle-free investment experience.

  • Spending: Citi Plus® Debit Mastercard® and Citi Plus® Credit Card bring clients a world of privileged shopping rewards while spending with these cards also boosts their saving interest rate by 0.3% p.a [3].

o Spending with Citi Plus® Debit Mastercard® offers up to 1% cashback[5], and with Citibank Global Wallet, clients can exchange foreign currencies at preferred rates[6], and then spend with the debit card for online/ in-store shopping and withdraw cash overseas directly with foreign currency accounts. Citi does not charge any handling fees[7] for cash withdrawals made with the card at any overseas ATMs (including Citi and Mastercard® ATMs).

o Citi Plus® Credit Card is tailor-made for Citi Plus® clients and has no annual fee. Payments for online shopping and fitness memberships can earn up to 3X reward points, while clients can also instantly offset spending anytime with Citi Pay with Points and get free purchase protection insurance.

  • One App to do it all: Citi Mobile® App enables clients to transfer funds, invest, spend, and more at their fingertips. In-app messaging is also available 24/7 to offer customer support promptly.

From now until April 30, clients can team up with their families and friends to join Citi Plus® to unlock an additional bonus savings rate of up to 6% p.a. [8] via ‘Citi Interest Booster’. For more information, please visit https://www.citibank.com.hk/english/banking/citi-plus/.

###

Investment in derivatives involves risks. Investors should understand the nature of the products before they make investment decisions.

To borrow or not to borrow? Borrow only if you can repay.



[1] “Wealth Digest” will be available soon, please visit citibank.hk/citiplus for updates.

[2] “Money Goal” will be available soon, please visit citibank.hk/citiplus for updates.

[3] Terms and Conditions for Citi Interest Booster: https://www.citibank.com.hk/english/banking/pdf/interest-booster-tnc.pdf

[4] Customer can enjoy the investment services by opening the investment accounts via the app separately.

[5] Enjoy up to 1% cash rebate for every point-of-sale purchase or online purchase for the first 6 months of card issuance, and up to 0.5% thereafter.

[6] Citibank Global Wallet supports 12 currencies: AUD, CAD, CHF, CNY, EUR, GBP, HKD, JPY, NZD, SGD, THB and USD. Before shopping at overseas shops or online, prepare sufficient foreign currencies in the account and this service will select the corresponding currency and directly debit from the account when the client spends. Citibank will not charge the foreign currency handling fee.

[7] For overseas withdrawals made with Global Wallet, the withdrawal amount, together with any surcharge levied by the overseas ATM operator, will be directly deducted from the relevant foreign currency account. For overseas withdrawals not made with Global Wallet, Citi does not charge any flat handling fee and charges a conversion spread up to 2.4% of the Hong Kong Dollar equivalent amount which includes the withdrawal amount and any surcharge levied by the overseas ATM operator. Please refer to the fees and charges for details.

[8] Terms and Conditions apply.

About Citi

Citi, the leading global Bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube:

www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi |

LinkedIn: www.linkedin.com/company/citi.

Continue Reading

News

Hong Kong Productivity Council and Hong Kong Computer Society Sign Pact to Enhance the Adoption of Emerging Technologies in Hong Kong

gbafNews28

HONG KONG SAR – Media OutReach – 22 February 2021 – The Hong Kong Productivity Council (HKPC) and the Hong Kong Computer Society (HKCS) today signed a Memorandum of Understanding (MoU) to form a strategic partnership in driving the adoption of emerging technologies in Hong Kong.

Mr Mohamed Butt, Executive Director of HKPC (left), and Ir Dr Ted Suen, MH, President of HKCS, sign a Memorandum of Understanding in which HKPC and HKCS will form a strategic partnership in driving the adoption of emerging technologies in Hong Kong.

Under the two-year arrangement, HKPC and HKCS will collaborate on talent development, education and promotion for emerging technologies to support the industry demand with focus in the areas of 5G, artificial intelligence (AI), cloud computing, cyber security, data analytics, Internet of Things (IoT) and robotics. This collaboration also signals HKPC’s relentless drive to invest in and build technologies that matter for Hong Kong in areas including reindustrialisation, SME and start-up support, intelligent manufacturing, digitalisation and cyber security, FutureSkills and smart and green living. HKCS members and local IT professionals will definitely benefit from this collaboration.

Mr Mohamed Butt, Executive Director of HKPC, said, “Being the expert of Industry 4.0 and Enterprise 4.0, HKPC has a team of technical professionals with a good grasp of technology research and development and advanced technologies such as IoT, big data analytics, AI and robotics, smart manufacturing. Our professional knowledge and acute technology sense will certainly help achieve more effective use of this collaboration.”

Dr Ted Suen, MH, President of HKCS, said, “With the continuous expansion of emerging technologies such as 5G and AI, coupled with the impact of the COVID-19 pandemic, many enterprises need to accelerate digital transformation to meet actual situation needs. The signing of the MoU will further strengthen collaboration between both parties, especially in the promotion of the application of emerging technologies.”

HKPC will set out a framework with HKCS to promote technology training courses organised by HKPC to its members and offer its government funding advisory support through SME ReachOut. HKCS, in turn, will recognise the relevant technology training courses offered by HKPC as continuing professional development activities and share the insights of the skills demand from the industries for HKPC to design training courses. Both sides also pledge to jointly promote and co-organise events related to emerging technologies such as seminars, webinars and workshops.

To mark the launch of the new collaboration, a webinar was held today with HKPC and HKCS experts sharing their insights of the Agile approach, intelligent automations and how they could enable enterprises to accelerate digital transformation.

About Hong Kong Productivity Council

The Hong Kong Productivity Council (HKPC) is a multi-disciplinary organisation established by statute in 1967, to promote productivity excellence through integrated advanced technologies and innovative service offerings to support Hong Kong enterprises. HKPC is the champion and expert in facilitating Hong Kong’s reindustrialisation empowered by i4.0 and e4.0 — focusing on R&D, IoT, big data analytics, AI and Robotic technology development, digital manufacturing, etc., to help enterprises and industries upgrade their business performance, lower operating costs, increase productivity and enhance competitiveness.


The Council is a trusted partner with comprehensive innovative solutions for Hong Kong industries and enterprises, enabling them to achieve resources and productivity utilisation, effectiveness and cost reduction, and enhanced competitiveness in both local and international marketplace. It offers SMEs and startups immediate and timely assistance in coping with the ever-changing business environment, accompanying them on their innovation and transformation journey.


In addition, HKPC partners and collaborates with local industries and enterprises to develop applied technology solutions for value creation. It also benefits a variety of sectors through product innovation and technology transfer, with commercialisation of multiple market-driven patents and technologies, bringing enormous opportunities abound for licensing and technology transfer, both locally and internationally.


For more information, please visit HKPC’s website: www.hkpc.org.


About Hong Kong Computer Society


Founded in 1970, the Hong Kong Computer Society (HKCS) is a recognised non-profit professional organisation focused on developing Hong Kong’s Information Technology (IT) profession and industry. Their members come from a broad spectrum of Hong Kong’s IT community, from corporations to like-minded individuals, all coming together to raise the profile and standards of the IT profession and industry. As a well-established IT professional body, the Society is committed to professional and industry development as well as community services to ensure the IT sector continues to make a positive impact on peoples’ lives with three main goals, namely, 1) talent cultivation and professional development, 2) industry development and collaboration, and 3) the effective use of IT in our community.

For more details, please visit HKCS’s website http://www.hkcs.org.hk

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News1 hour ago

HKGSEO Provides Free Website SEO Analysis and Consulting Services

HONG KONG SAR – Media OutReach – 22 February 2021 – The COVID-19 epidemic has lasted for nearly a year....

gbafNews28 gbafNews28
News1 hour ago

Media OutReach Expands into China with Strategic Partnership with Xinhua Finance Agency

The newswire continues growing its foothold in Asia by opening its 7th office in the region   HONG KONG SAR...

gbafNews28 gbafNews28
News1 hour ago

Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

HONG KONG SAR – Media OutReach – 22 February 2021 – This announcement is made by Ocumension Therapeutics (the “Company“,...

gbafNews28 gbafNews28
News1 hour ago

Citi Plus® Official Launch Ceremony

HONG KONG SAR – Media OutReach – 22 February 2021 Photo 1 Mr Lawrence Lam, Consumer Business Manager of Citibank...

gbafNews28 gbafNews28
News1 hour ago

Hong Kong Productivity Council and Hong Kong Computer Society Sign Pact to Enhance the Adoption of Emerging Technologies in Hong Kong

HONG KONG SAR – Media OutReach – 22 February 2021 – The Hong Kong Productivity Council (HKPC) and the Hong...

gbafNews28 gbafNews28
News1 hour ago

Citibank Officially Launches Citi Plus®

Co-creating With Target Clients to Suit Their Banking and Investment Needs Fostering Financial Education to Level-Up Digital Natives Through Mobile...

gbafNews28 gbafNews28
News1 hour ago

Kerry Logistics Network Extends Winning Streak at the Quamnet Outstanding Enterprise Awards for Sixth Year Running

HONG KONG SAR – Media OutReach – 22 February 2021 – Kerry Logistics Network Limited (‘Kerry Logistics Network’; Stock Code...

gbafNews28 gbafNews28
News1 hour ago

Black Spade Capital Aims to Build an SPAC-themed Portfolio

HONG KONG SAR – Media OutReach – 22 February 2021 – 2020 proved to be a great year for Special...

gbafNews28 gbafNews28
News1 hour ago

Nexstgo comprehensively enhances its range of NEXSTMALL BIZ business solutions

Giving impetus to the development of SMEs with digital strategies to maintain their competitiveness under the ‘new normal’   HONG...

gbafNews28 gbafNews28
News1 hour ago

Unique French-English bilingual programme at the Canadian International School (CIS) expanding from August 2021

SINGAPORE – Media OutReach – 22 February 2021 – The Canadian International School (CIS) in Singapore is delighted to announce...